Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
WORLD HEART CORP (WHRT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2012 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of World Heart Corporation",
"Amended and Restated Bylaws of World Heart Corporation",
"HEARTWARE COMPLETES ACQUISITION OF WORLD HEART CORPORATION Framingham, Mass. and Salt Lake City, Utah, August 2, 2012 - HeartWare International, Inc. , a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the closing of the acquisition of World Heart Corporation following the approval of the transaction today by World Heart stockholders. Under the terms of the merger agreement, HeartWare acquired all of the outstanding voting securities of World Heart for merger consideration of approximately $8,000,000 in HeartWare common stock, as calculated in accordance with the terms of the merger agreement. Each share of World Heart common stock has been converted into the right to receive..."
07/02/2012 8-K Quarterly results
04/24/2012 8-K Form 8-K - Current report
04/03/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among HeartWare International, Inc., Ocean Acquisition Holding Inc. and World Heart Corporation",
"Form of Voting Agreement entered into between HeartWare International, Inc., Ocean Acquisition Holding Inc. and the following stockholders of World Heart Corporation: Austin W. Marxe, New Leaf Ventures II, L.P., Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P",
"License Agreement, by and between World Heart Corporation and HeartWare International, Inc"
03/30/2012 8-K/A Other Events, Financial Statements and Exhibits
Docs: "HEARTWARE INTERNATIONAL EXPANDS INTELLECTUAL PROPERTY AND TECHNOLOGY PORTFOLIO THROUGH DEFINITIVE AGREEMENT TO ACQUIRE WORLD HEART CORPORATION FOR US$8 MILLION"
02/23/2012 8-K Form 8-K - Current report
08/18/2011 8-K Form 8-K - Current report
07/29/2011 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "WorldHeart will end its Levacor® VAD program and will focus on developing its next-generation MiFlow™ miniature ventricular assist device"
06/28/2011 8-K Submission of Matters to a Vote of Security Holders
02/14/2011 8-K Form 8-K - Current report
02/09/2011 8-K Form 8-K - Current report
01/12/2011 8-K Form 8-K - Current report
12/06/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Levacor VAD® Hemocompatibility Analysis Presented at European Mechanical Circulatory Support Summit Preservation of an Important Blood Factor to Prevent Bleeding Observed"
10/20/2010 8-K Form 8-K - Current report
10/14/2010 8-K Form 8-K - Current report
08/16/2010 8-K Form 8-K - Current report
08/03/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "WorldHeart Announces Tenth Levacor™ VAD Implant in US BTT Study"
07/27/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "WorldHeart Receives FDA Approval to Add Clinical Sites in Levacor™ VAD Bridge-to-Transplant Study"
07/06/2010 8-K Form 8-K - Current report
06/21/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "WorldHeart Announces Two Implants of the Levacor™ VAD"
06/16/2010 8-K Form 8-K - Current report
06/14/2010 8-K Submission of Matters to a Vote of Security Holders
05/17/2010 8-K Quarterly results
Docs: "WorldHeart Reports First Quarter 2010 Financial Results Status of the Bridge-to-Transplant Clinical Study and Field Corrective Action Salt Lake City, UT — May 17, 2010: World Heart Corporation , a developer of mechanical circulatory systems, today reported its results for the first quarter 2010. WorldHeart reported a net loss for the three months ended March 31, 2010 of $9.7 million, or a $0.68 loss per basic and diluted share, compared to a $3.7 million net loss, or a $0.28 loss per basic and diluted share for the same period in 2009. The increase in net loss and loss per share for the three months ended March 31, 2010 as compared to the same period on 2009 was primarily the result of a one-time, non-cash loss on liquidation of foreign entity of $6.3 million as a result of WorldHeart's ch..."
05/03/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "WorldHeart Appoints Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs Salt Lake City, UT — April 30, 2010: World Heart Corporation , a developer of mechanical circulatory systems, announced the appointment of Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs. Dr. Woodard will be responsible for clinical affairs and will also guide the development of WorldHeart's next- generation technologies. Dr. Woodard most recently served as Chief Scientific Officer for Ventracor Limited: an Australian-based public company focused on the development of left ventricular assist devices for late-stage heart failure patients. Prior to that, Dr. Woodard has served in various senior management positions in a number of medical device companies including, Micromedic...",
"Letter of Agreement with John Woodard"
04/13/2010 8-K Form 8-K - Current report
03/30/2010 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/23/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "WorldHeart Announces Levacor VAD Implant at the University of Utah Salt Lake City, UT — March 23, 2010: World Heart Corporation , a developer of mechanical circulatory systems, announced today that the University of Utah Hospital in Salt Lake City, Utah has successfully implanted its first Levacor™ Ventricular Assist Device . The University of Utah has extensive experience in the VAD field and is the second implanting site nationwide in the Levacor VAD Bridge-To-Transplant Study. This is the fourth implant with the Levacor VAD since the inception of the BTT study. Dr. Craig Selzman, cardiac surgeon and the University of Utah's surgical Principal Investigator for the study commented, “We are excited to participate in the Levacor VAD BTT Study and to provide a unique technology to our patien..."
03/09/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Summary of 2010 Performance Bonus Program for Executive Officers and Other Employees"
03/01/2010 8-K Quarterly results
Docs: "WorldHeart Reports 2009 Financial Results SALT LAKE CITY, March 1, 2010 — - World Heart Corporation, a developer of mechanical circulatory systems, today reported the net loss for the year ended December 31, 2009 of $16.7 million, or a $1.26 loss per basic and diluted share, compared to a $25.3 million net loss, or a $4.37 loss per basic and diluted share in 2008. The decrease was primarily the result of one-time, non-cash clinical and marketing expenses of $6.5 million and one-time debt inducement expense of $3.9 million that we recognized in 2008 related to warrants issued to a strategic partner and the subsequent conversion of debt to common stock. The decrease in clinical and marketing expenses and the debt inducement expense in 2009 was offset by increases in research and development ..."
02/10/2010 8-K Form 8-K - Current report
02/10/2010 8-K/A Other Events
02/05/2010 8-K Appointed a new director
Docs: "NASDAQ Stock Market Confirms WorldHeart's Compliance with NASDAQ Listing Rule 5605",
"WorldHeart Announces the Election of a New Director"
02/04/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "WorldHeart Participates in NIH Award for Further Development of a Miniaturized MagLev VAD Salt Lake City, UT — February 4, 2010: —- World Heart Corporation announced today that it was part of a consortium awarded a $5.6 million, 4-year contract by the National Institutes of Health to further develop the PediaFlow™ VAD to clinical trial readiness. The PediaFlow VAD, a miniaturized implantable fully magnetically levitated blood pump, is intended for neonates and infants. It has evolved significantly through design and development with funding from a previous NIH contract, and supplemental funding and technology contributions from WorldHeart. This device is now approximately the size of a AA battery and was successfully evaluated in a multi-month animal experiment in 2009. Led by the Universi..."
01/22/2010 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Five-Year Warrant",
"Form of 15-Month Warrant",
"Securities Purchase Agreement, by and among World Heart Corporation and the purchasers listed on the signature pages thereto",
"Registration Rights Agreement, by and among World Heart Corporation and the purchasers listed on the signature pages thereto"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy